Xiao Lin, a 25-year-old girl from Guangzhou, was at an age where she should be dedicating herself to her passion, enjoying life with friends, and working hard toward her dreams. Yet, three years ago, she unexpectedly encountered cancer. Today, thanks to the meticulous care of the Luo Pengfei · Wang Jian Programmatic Interventional Oncology Research Team at the Fifth Oncology Department of Guangdong Pharmaceutical University Guangzhou Fosun Chancheng Hospital (Guangzhou Xinshi Hospital), she has successfully stabilized her condition and is gradually returning to normal life. In the warm spring of 2026, she is embracing the dawn of her recovery.
Xiao Lin is a native of Guangzhou. As a typical "post-95s" young woman, she loves sports, enjoys life, and, like other girls her age, holds boundless hopes for the future. However, this promising life was completely shattered in March 2023. During a routine physical examination, an unusual shadow was detected on her liver, and doctors immediately recommended further tests. "I'm only 22, I've always been healthy, nothing will happen," she tried to reassure herself, pretending to be calm, though a vague unease lingered within her.
But after three consecutive follow-up examinations at tertiary hospitals, the final diagnosis brought the same devastating news: primary liver cancer. At that moment, Xiao Lin's psychological defenses completely crumbled, and tears streamed down her face uncontrollably. "It wasn't the pain; it was the fear—the fear that my life would stop right here." Fortunately, her condition was not yet advanced. Local doctors suggested systemic chemotherapy, but having heard about its severe side effects and grueling process, Xiao Lin was terrified. After much contemplation, she refused traditional chemotherapy and began searching for a gentler treatment path better suited for a young patient.
Just as she felt lost and helpless, a friend recommended interventional oncology to her. This approach is highly targeted, with far fewer toxic side effects than conventional radiotherapy and chemotherapy, making it more aligned with the needs of a young patient. Xiao Lin then learned that the Luo Pengfei · Wang Jian Programmatic Interventional Oncology Research Team at the Fifth Oncology Department of Xinshi Hospital has decades of clinical experience in interventional oncology. The team's independently developed "Programmatic Standardized Procedure for Inactivating Tumor Biological Activity" holds international patents and is considered a benchmark therapy in China's interventional oncology field. Moreover, Professor Luo Pengfei is a renowned authority in interventional radiology oncology in China. This information rekindled hope for Xiao Lin, who was on the verge of despair.
In April 2023, Xiao Lin sought treatment at the Fifth Oncology Department of Xinshi Hospital, where Professors Luo Pengfei and Wang Jian personally received her. Facing the young and vulnerable Xiao Lin, the two professors patiently listened to her concerns, carefully explained her condition, and devised a treatment plan that balanced efficacy with quality of life, all while providing continuous, warm reassurance. Professor Luo Pengfei encouraged her, saying, "You are so young, with endless possibilities ahead. Don't give up. Trust us, let's work together!" These simple words were like a beam of light illuminating Xiao Lin's bleak path against cancer, giving her the courage to persevere. The two professors conducted multiple joint consultations. Considering Xiao Lin's condition, age, and physical status, they followed the principle of three steps—"control the tumor, shrink the tumor, reduce the tumor"—and tailored a minimally invasive interventional treatment plan that was standardized, had low toxicity, and was highly targeted. From April 2023 to October 2025, Professor Wang Jian personally performed the procedures, administering a series of minimally invasive interventional treatments for Xiao Lin, including transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), with meticulous precision throughout to minimize damage to her body.
Thanks to the scientific programmatic diagnosis and treatment and the advantages of minimally invasive techniques, Xiao Lin's condition saw positive turns time and again. The biological activity of the tumor continuously diminished, and the tumor itself kept shrinking. Midway through treatment, the liver tumor had shrunk from its initial size to 60×30×67 mm. During a follow-up examination in October 2025, the lesion in segment 7 of the liver showed significant improvement, with the tumor volume reduced to just 21×17 mm. Each improvement confirmed by follow-up boosted Xiao Lin's confidence. She said determinedly, "With such professional doctors helping me, I absolutely cannot give up."
As of this month, Xiao Lin has been stable in her fight against cancer for three years. Her condition remains under long-term control, and her physical state is improving steadily. Because interventional treatments require short hospital stays and allow for quick recovery, she never had to give up her work or hobbies. After her condition stabilized, she returned to her career, continuing to pursue her passion. In her free time, she still insists on running and working out, using exercise to document her rebirth and growth.
Today, Xiao Lin has long emerged from the shadow of cancer, gaining a deeper understanding of life. She cherishes every single moment of the present and has learned to make peace with herself. Xiao Lin is eternally grateful to Professors Luo Pengfei and Wang Jian and their team for their treatment. It is this combination of professionalism and warm care that allowed her, in the prime of her life, to break free from death's grip and embrace her own bright future once more.
